At the ESCRS 2014 ZEISS is offering cataract surgeons a greater diversity of products for enhanced safety and presenting a new product line for basic diagnostics

At the summer meeting of the European Society of Cataract and Refractive Surgery (ESCRS), which is taking place this year in London in combination with EURETINA, ZEISS is presenting innovative additions to its extensive product portfolio for cataract surgery.

The offering for basic diagnostics is being expanded. The IOLMaster® 700 with SWEPT Source Biometry™ and the CT LUCIA® IOL are being added to the product line for intraocular lens implantation. ZEISS also shows major additions to its offerings of retina and glaucoma diagnostic products. In the field of refractive laser surgery more and more users all over the world are opting for SMILE, the third generation of laser vision correction. ZEISS is benefiting from increased numbers of users.

JENA/Germany, 16/09/2014.

As one highlight of this year's meeting, ZEISS is presenting the first system with SWEPT Source Biometry: in addition to optical biometry, the IOLMaster 700 delivers OCT images over the entire length of the eye. According to the experts, this information will enable a reduction in refractive surprises in cataract treatment and permit more reliable results. Compared to current techniques in which the measuring result is derived from an A-scan curve, the image-based measurement of the IOLMaster 700 offers more certainty to both doctor and patient. The anticipated refractive result can be more reliably predicted.

As in the standard-setting IOLMaster 500, the system simplifies the workflow of toric IOL implantation by capturing a reference image of the limbal blood vessels, with the aid of which the cylinder axis can be displayed intraoperatively into the eyepiece of the surgical microscope as a navigation aid for the surgeon. This means that the new IOLMaster will be an important component of the ZEISS Cataract Suite markerless that provides surgeons with a smooth workflow in the implantation of high-quality intraocular lenses.

ZEISS now offers its customers with even more possibilities for the treatment of cataract patients. The introduction of the monofocal IOL CT LUCIA is sharply focused on doctors who prefer the hydrophobic C-loop design. Thanks to the innovative preloaded injector system, the surgeons benefit from straightforward and efficient workflows, and patients from optimal refractive outcomes¹ through special ZEISS optics. ZEISS now offers the most comprehensive IOL portfolio on the market. The new lens rounds off the well-established range of hydrophilic MICS IOLs with an extensive diopter range.

Furthermore, ZEISS can now provide its customers with a more comprehensive offering for basic ophthalmic diagnostics than ever before: The Essential Line provides all eye specialists with access to ZEISS quality from the start and includes not only the proven slit lamps with imaging functions, but also products for objective and subjective refraction, examinations of the retina and measurement of intraocular pressure. The new offering includes the VISUPHOR® 500 digital phoropter, the VISUSCREEN® 100/ 500 acuity charts and the portable VISUSCOUT® 100 fundus camera.

At ESCRS/EURETINA, ZEISS also shows major additions to its offerings of retina and glaucoma diagnostic products. The new FORUM Retina Workplace presents data in an intuitive Triple Display: OCT data are automatically registered to fundus images and thickness and volume values are shown over time. At a glance, doctors can compare current and prior images as well as measurements to help them quickly determine the best treatment plan.

In the area of glaucoma, ZEISS will be previewing its wide view tools for glaucoma assessment: the new Anterior Segment Package and PanoMap for CIRRUS HD-OCT. ZEISS is the first company to present a full anterior chamber image in its retinal OCT products to help doctors identify patients at risk for angle closure. The Anterior Segment Package also introduces OCT Goniometry, a non-contact method of quantifying and tracking angle status. High-definition angle scans reveal anatomical details facilitating placement of the measurement tools. The new CIRRUS PanoMap combines macular and disc maps in a single wide field display to make visible structural damage across the entire posterior pole. The new retina and glaucoma offerings will be available early next year.

"We see ourselves as a solutions provider in ophthalmology and aim to optimally support our customers along the entire diagnostic and treatment chain," says Dr. Ludwin Monz, CEO of Carl Zeiss Meditec AG. "Our goal is to enable eye specialists to achieve the best possible clinical result for each and every patient."

A further focus of this year's ZEISS presentation at the meeting is on the products for refractive surgery. "The needs of doctors and patients in refractive laser surgery are very different. To cater to this diversity, we also offer a broad product portfolio," says Ludwin Monz. This includes the MEL® 80 and MEL® 90 excimer lasers and the VisuMax® femtosecond laser. According to Monz, the strong demand for SMILE technique is clear confirmation of the company's policy: more than 125,000 procedures have already been successfully performed worldwide; 400 trained doctors offer the treatment in more than 230 facilities in 38 countries. The approval procedure in the USA is also proceeding positively. Before the start of the ESCRS, more than 330 persons will have already been treated as part of the clinical trials being conducted in the US.

Visit us at booth at the ZEISS booth E14.
You can find further information on our product innovations and events at the ESCRS at:

Press contact:
Jann Gerrit Ohlendorf, Group Communications, Carl Zeiss Meditec AG
Phone: +49 3641 220-331, Email: press .meditec @zeiss .com

For investors:
Sebastian Frericks, Investor Relations, Carl Zeiss Meditec AG
Phone: +49 3641 220-116, Email: investors .meditec @zeiss .com

Brief profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases - including implants and consumable materials. The company creates innovative visualisation solutions in the field of microsurgery. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In financial year 2012/2013 (ended 30 September) the Group's more than 2,500 employees generated revenue of almost € 906 million.

The head office of Carl Zeiss Meditec is in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Research and Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

Carl Zeiss offers innovative solutions for the future-oriented markets of Medical and Research Solutions, Industrial Solutions, Eye Care and Lifestyle Products. Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Foundation.

  • 1 Maedel S et al. Effect of heparin coating of a foldable intraocular lens on inflammation and capsular bag performance after cataract surgery. JCRS 2013